tbuckley/cabot-search huggingface dataset:
Who calls the breast care nurses – the rich, the poor or the poorly?.
Authors: A Chaudhry, E Massey, T Roe, R Price, S Scarrott, C Chan
Journal: Cancer Research (2009)

Abstract Abstract #6094 Introduction: Breast care nurses (BCNs) are valuable members of the team; they provide advice, counselling and act as patients' advocates. We have previously demonstrated the worth of BCNs in our UK centre1 and the high number of calls they receive from patients and family. In this study, we investigate factors that might influence call rates from individual patients. We have examined the effect of patient age, prognosis and social deprivation on demand for this service.&amp;#x2028; Methods: Our BCNs collect prospectively daily call sheets. These sheets include hospital number, age, type of call (phone or face to face), duration of call, purpose of call and outcome. We have examined breast nurse call sheets over a six-month period. The patients' home zip codes were also collected and allocated to the correct electoral ward (small geographical areas with average population of 5500). Using data from the UK National Census in 2000, information on social status was derived from the patients' zip codes and given as the Index of Multiple Deprivation (ID2000). The ID2000 has both an ID2000 score and ID2000 ranking for different electoral wards across England. Low ID2000 scores and high ID2000 rankings correspond to areas of affluence. Prognostic information was derived using the Nottingham Prognostic Index (NPI). The data were analysed by Spearman rank correlation using Statview 5.0 (SAS Inc) software comparing call rate to age, NPI and ID2000 scores &amp; rankings.&amp;#x2028; Results: During a six-month period, 1188 patients contacted the breast cancer nurse specialists in the NHS and private setting. 204 (17.1%) patients contacted their BCN once; 228 (19.1%) twice; 264 (22.2%) three times and 492 (41.4%) of patients called four times or more.&amp;#x2028; Analysis by Spearman rank correlation of number of calls against age (Rho = -0.009, p=0.90), NPI (Rho = 0.068, p=0.40), ID2000 scores (Rho = 0.058, p=0.41) &amp; ID20000 rank (Rho = -0.060, p=0.40) show no evidence of a relationship between age, prognosis or deprivation and the need to access BCNs.&amp;#x2028; Conclusions: The BCNs provide a valuable service to patients with breast cancer. This support continues throughout the individual patient's cancer journey. In Gloucestershire, the need for support appears to be independent of age, prognosis and social status.&amp;#x2028; 1 Counselling women with breast cancer - whose line is it anyway?&amp;#x2028; F G Court, S Scarrott, M Cassidy-Gray, A Thomas, S Vestey, J Bristol, M Ghilchik, H Y Chan&amp;#x2028; Abstract 6045 - SABCS 2007. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6094.
A novel stent for management of duodenal obstruction
Authors: H. Cai, X. Jiang, Q. Dong, H. Li, W. Xie
Journal: Endoscopy (2009)

A 61-year-old woman was admitted for acute pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). At 1 week after standard treatments, the symptoms of pancreatitis disappeared. However, the patient could not eat anything, vomited repeatedly and developed recurrent biliary infections. Computed tomography (CT) revealed an enlarged pancreatic head (4 × 6 cm; [Fig. 1 a]). A jejunal tube and a nasogastric tube were introduced. The drainage volume was around 1500 ml/day and did not decrease in the following 2 months. Iodine swallow revealed an obstruction at the distal descending duodenum and the proximal horizontal duodenum ([Fig. 1 b]).
Abstract 681: PTX-008, a novel galectin-1 targeting agent, improves the effects of cytotoxic drugs in colon cancer cells
Authors: Lucile Astorgues-Xerri, Maria Serova, Maria E. Riveiro, Esteban Cvitkovic, Kay Noel, Eric Raymond, Sandrine Faivre
Journal: Cancer Research (2011)

Abstract Background: Addition of targeted therapies has been shown to potentiate the activity of cytotoxic drugs. Compounds with innovative mechanism of action such as PTX-008, a novel galectin-1 targeting agent, might represent an interesting candidate for cytotoxic-based combinations. We explored the effect of PTX-008 in combination with several drugs commonly used in cancer chemotherapy such as cisplatin, oxaliplatin, 5-FU, 5’-DFUR, taxotere and gemcitabine in colon cancer cell lines. Methods: Antiproliferative effects were evaluated in two human colon (Colo205 and HT29) cancer cell lines by MTT assay. Effects of different schedules of exposure of PTX-008-based combinations were determined by median effect plot analysis (Chou &amp; Talalay). Results: PTX-008 induced significant growth inhibition at concentrations below 10 µM in HT29 and Colo205 cancer cell lines. Combination of PTX-008 with cisplatin and oxaliplatin was additive or synergistic in both Colo205 and HT29 cells for all administration schedules. Combination of PTX-008 with antimetabolites 5-FU and 5’-DFUR was synergistic for sequential administration schedule, especially when PTX-008 was given prior to 5-FU and 5’-DFUR in colon cancer cells. Simultaneous exposure to these drugs induced additive effects. Combination with taxotere was at least additive using all schedules of administration. PTX-008/gemcitabine combination were highly synergistic in Colo205 and HT29 cells for sequential schedules and additive/synergistic for simultaneous administration. Conclusions: Combination studies showed that PTX-008 displays at least additive, often synergistic effects with a wide range of cytotoxic drugs (including cisplatin, oxaliplatin, 5-FU, gemcitabine and taxotere). Those data provide preliminary evidences that inhibition of galectin-1 using PTX-008 may be an attractive approach for combinations with anticancer drugs in clinical trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 681. doi:10.1158/1538-7445.AM2011-681
Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment
Authors: Anna E. Vilgelm, C. Andrew Johnson, Nripesh Prasad, Jinming Yang, Sheau-Chiann Chen, Gregory D. Ayers, Jeff S. Pawlikowski, Dayanidhi Raman, Jeffrey A. Sosman, Mark Kelley, Jeffrey A. Ecsedy, Yu Shyr, Shawn E. Levy, Ann Richmond
Journal: JNCI Journal of the National Cancer Institute (2015)

Background:Tumor cell senescence is a common outcome of anticancer therapy. Here we investigated how therapy-induced senescence (TIS) affects tumor-infiltrating leukocytes (TILs) and the efficacy of immunotherapy in melanoma.
Sharing the Care to Improve Access to Primary Care
Authors: Amireh Ghorob, Thomas Bodenheimer
Journal: New England Journal of Medicine (2012)

Gaining prompt access to primary care is a growing concern for all American adults. In Massachusetts, average wait times for new patients to obtain an internal-medicine appointment rose by 82% in the 2 years after health insurance coverage was expanded; current wait times average 36 days for family medicine and 48 days for internal medicine.1 In a 2011 national survey, 57% of patients who were sick and needed medical attention could not obtain access to care promptly, up from 53% in 2006.2 The reason for the access problem is an imbalance between demand for care and capacity to provide care. . . .
P982 MULTIDISCIPLINARY TREATMENTS IMPROVE SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: ANALYZING THE SURVIVAL RATE OF PATIENTS AFTER SORAFENIB ADMINISTRATION
Authors: N. Hattori, K. Tsuchiya, N. Nakakuki, H. Takada, S. Matsuda, S. Kaneko, M. Muraoka, N. Tamaki, Y. Yasui, R. Osaki, S. Suzuki, T. Hosokawa, H. Nakanishi, J. Itakura, Y. Takahashi, M. Kurosaki, N. Izumi
Journal: Journal of Hepatology (2014)
Feminization of the workforce in urologic oncology: Socioeconomic, workforce, and quality-of-life issues.
Authors: Nicholas Pruthi, E. Sophie Spencer, Matthew Lyons, Peter Greene, Matthew Edward Nielsen, Raj Pruthi, Mathew Raynor, Eric Wallen, Michael Woods, Angela Smith
Journal: Journal of Clinical Oncology (2015)

72 Background: In recent years, the proportion of women in urology has been increasing, from &lt;0.5% in 1981 to approximately 10% today. Nearly 25% of students matching in urology are now female. Our objective was to characterize the female workforce in urologic oncology and compare income, workload, and job satisfaction to the male counterpart and a non-oncology career. Methods: We queried the American Urological Association (AUA) domestic membership of practicing urologists regarding socioeconomic, workforce, and quality of life issues. A total of 6,511 valid survey invitations were sent via e-mail, and 848 responses were collected for a total response rate of 13%. Results: The percentage of females in the urology workforce is 11%, and only 4% of urologists with an oncology focus are female. Of those with a primary focus that is non-oncology, 13% are female. Demographics, income, and practice characteristics between these groups are shown in the Table below. Conclusions: Females appear to be relatively under-represented in urologic oncology, with lower income among women both in oncology and non-oncology fields. [Table: see text]
Abstract 3677: Prediction of oral cancer recurrence at post-surgery follow-up using fluorescence visualization
Authors: Catherine F.Y Poh, Lang Wu, Kevin Ko, P. Michele Williams, Miriam P. Rosin
Journal: Cancer Research (2011)

Abstract Background: Recurrence is observed in up to 30% of surgically treated high-risk oral lesions (HRLs, severe dysplasia, carcinoma in situ and cancer) and is associated with poor prognosis. Reactive tissue change observed post-treatment often masks recurrence and makes early detection difficult. New advances using fluorescence visualization (FV) represent a promising approach to this problem that may facilitate early detection of disease recurrence. Objectives: 1) To identify FV alterations post-treatment of HRLs and 2) To determine whether a relationship exists between FV alterations and local recurrence. Methods: In the BC Oral Cancer Longitudinal Study, we have recruited ∼400 HRLs with surgical treatment as the primary modality. Patients eligible for this analysis included those that had an initial follow-up appointment within 6 months of surgery with at least 2 follow-up appointments within the first year of treatment, with each visit involving FV examination of the treatment site. Recurrence was defined as the presence of biopsy-proven HRLs. The ‘plateau’ of the FV during the follow-ups is defined as the change of FV measurement in width within ± 1 mm (superior-inferiorly) in various time intervals of 3, 6, 9, or 12 months. Results: A total of 198 patients were identified of which 24 (12%) had lesion recurrence at the previously treated site. There was no difference in gender, age, ethnicity, smoking habit, anatomical site, primary diagnoses, and follow-up time between the recurrence and non-recurrence groups. The duration of plateau was longer in non-recurrence group compared to those in recurrence group (P = 0.03). When we examined the duration ‘plateau’ at various intervals of follow-ups, among 166 patients/lesions with at least 9 months follow-ups, we found out that the presence of plateau was more frequent in the non-recurrence group than those recurrent case (P = 0.03). Using linear mixed effects and logistic regression analyses, there was a significant difference of the individual slopes between recurrence and non-recurrence group (P = 0.001), adjusted for the individual intercepts (i.e., the original FV width). Conclusion: The stability, i.e., timing and duration of the plateau, of the FV alteration during post-surgical follow-ups can be potentially used to predict local recurrence of HRLs. (Supported by Supported by grant R01 DE17013 from the National Institute of Dental and Craniofacial Research and grant CCSRI-20336 from Canadian Cancer Society Research Institute; Canadian Institute for Health Research and Michael Smith Foundation from Health Research) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3677. doi:10.1158/1538-7445.AM2011-3677
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force
Authors: Evelyn P. Whitlock, Brittany U. Burda, Selvi B. Williams, Janelle M. Guirguis-Blake, Corinne V. Evans
Journal: Annals of Internal Medicine (2016)

The balance between potential aspirin-related risks and benefits is critical in primary prevention.To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention.PubMed, MEDLINE, Cochrane Central Register of Controlled Trials (2010 through 6 January 2015), and relevant references from other reviews.Randomized, controlled trials; cohort studies; and meta-analyses comparing aspirin with placebo or no treatment to prevent CVD or cancer in adults.One investigator abstracted data, another checked for accuracy, and 2 assessed study quality.In CVD primary prevention studies, very-low-dose aspirin use (≤100 mg daily or every other day) increased major gastrointestinal (GI) bleeding risk by 58% (odds ratio [OR], 1.58 [95% CI, 1.29 to 1.95]) and hemorrhagic stroke risk by 27% (OR, 1.27 [CI, 0.96 to 1.68]). Projected excess bleeding events with aspirin depend on baseline assumptions. Estimated excess major bleeding events were 1.39 (CI, 0.70 to 2.28) for GI bleeding and 0.32 (CI, -0.05 to 0.82) for hemorrhagic stroke per 1000 person-years of aspirin exposure using baseline bleeding rates from a community-based observational sample. Such events could be greater among older persons, men, and those with CVD risk factors that also increase bleeding risk.Power to detect effects on hemorrhagic stroke was limited. Harms other than serious bleeding were not examined.Consideration of the safety of primary prevention with aspirin requires an individualized assessment of aspirin's effects on bleeding risks and expected benefits because absolute bleeding risk may vary considerably by patient.Agency for Healthcare Research and Quality.
SP0156 Latest Advances in Biological Treatment – Safety and Efficacy
Authors: L. Gossec
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Biologic therapies are very efficacious in chronic inflammatory diseases such as rheumatoid arthritis and spondyloarthritis. However, the increasing number of Biologic therapies, are making the decisions which patients have to take about care and treatment, more complicated. This talk will present some information about biologicals: why are they different from standard disease modifying drugs such as methotrexate? How are they administered? We will then discuss the latest advances in biological treatment, both in terms of drugs available and/or licensed, mechanisms of action, efficacy and safety. Where possible, we will see how these drugs might be used in a more targeted way in years to come when we are able to understand more about why some people respond to one biologic drug, but not another. <h3>Disclosure of Interest</h3> None Declared
Abstract 1294: Suppression of uPA in chemo-sensitization and p53 regulation in pancreatic cancer cells
Authors: Bharathi Gorantla, Swapna Asuthkar, Norman Estes, Jasti S. Rao, Christopher S. Gondi
Journal: Cancer Research (2012)

Abstract Despite new knowledge of the molecular profile of pancreatic cancer and its precursor lesions, survival rates have changed very little over the last 40 years. The ability to predict which patients would benefit most from surgical intervention and/or chemotherapy would be a great clinical asset. Researchers have demonstrated that uPA is frequently present in a higher concentration in the serum of pancreaticobiliary cancer patients. It is known that uPA is involved in ECM degradation and has been correlated with malignant transformation of cancer cells. Emerging data have suggested that the capability of a tumor to grow and propagate is dependent on a small subset of cells within a tumor called cancer stem cells (CSCs) or cancer initiating cells. Under in vitro cell culture conditions, these cells possess sphere-forming ability, which is known to be one of the properties of CSCs. Interestingly, the significance of this sphere formation ability still remains unclear. Recent studies have demonstrated that these sphere-forming cells acquired chemoresistance to cisplatin. In the present study, as observed by FACS analysis, we show that a sub-population of MIA PaCa-2 and PANC-1 pancreatic cancer cells possess cancer stem cell properties. RNAi-mediated suppression of uPA in these cells retarded their tumor forming ability in a nude mouse model. We also observed that uPA-suppressed MIA PaCa-2 and PANC-1 cells, after supplementation with uPA protein regained their cancer stem cell phenotype and showed increased expression of Lhx-2. To determine whether these sub-population cells possess any chemoresistance, we treated these cells with varying concentrations of gemcitabine (0-1000 nM) and observed that these cells were resistant to gemcitabine even at the 1000 nM concentration. Further suppression of uPA using siRNA in these cells sensitized these cells to gemcitabine. In addition, to determine whether uPA has any transcriptional role, we examined whether uPA interacted with any known transcription factors we used a TF-protein array. We observed that uPA interacted with Hoxa-5 very strongly. To further determine whether the interaction of uPA with Hoxa-5 invokes any regulatory response, we used a p53 promoter known to possess Hoxa-5 binding regions to drive a Luciferace gene, both with and without the presence of uPA. We observed that uPA retarded p53 promoter activity. Finally, nude mice implanted with MIA PaCa-2 cancer stem cells were susceptible to gemcitabine treatment after uPA downregulation. Taken together, these results indicate that targeting uPA can sensitize chemoresistant pancreatic cells to gemcitabine. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1294. doi:1538-7445.AM2012-1294
Paternity by Intrauterine Insemination with Sperm from a Man with 5α-Reductase-2 Deficiency
Authors: Melissa D. Katz, Isaac Kligman, Li-Qun Cai, Yuan-Shan Zhu, Carmel M. Fratianni, Ioannis Zervoudakis, Zev Rosenwaks, Julianne Imperato-McGinley
Journal: New England Journal of Medicine (1997)

Male pseudohermaphroditism results from the abnormal differentiation of male external genitalia in a genotypic male. One cause of male pseudohermaphroditism is a deficiency of 5α-reductase-2, the enzyme that converts testosterone to 5α-dihydrotestosterone in specific androgen-dependent target tissues.1–3 Males who are homozygous for the disorder usually present with pseudovaginal perineoscrotal hypospadias at birth. Most have distinct urethral and vaginal openings within a urogenital sinus and a clitoris-like phallus. Virilization occurs at puberty with phallic growth, rugation and pigmentation of the scrotum, and testicular descent.1–3 At this time, the voice deepens and muscle mass increases, with the development of a . . .
FRI0393 Predictive value of history of digital ulcers in a eustar cohort of patients with systemic sclerosis
Authors: C. Mihai, R. Landewé, D. van der Heijde, U. Walker, P. I. Constantin, R. M. Ionescu, S. Rednic, A. M. Gherghe, R. Sfrent-Cornăteanu, Y. Allanore, J. Avouac, L. Czirjak, D. Farge-Bancel, N. Damjanov, O. Kowal-Bielecka, F. van den Hoogen, A. Tyndall, M. Cutolo, U. Müller-Ladner, M. Matucci Cerinic
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Digital ulcers (DUs) have a prevalence of up to 36% in systemic sclerosis (SSc) patients and are a heavy burden, significantly reducing quality of life and function and leading to severe complications. <h3>Objectives</h3> To evaluate in SSc patients the hypothesis that a history of DUs at presentation may be a predictor of vascular outcomes and of overall clinical worsening and death. <h3>Methods</h3> All patients from the EUSTAR database (MEDS online), satisfying the 1980 ACR classification criteria for SSc, who had a follow-up of at least 3 years since inclusion or who have died, were included in the analysis. History of DUs at presentation as a predictor of disease progression or death was evaluated by univariate and multivariate Cox proportional hazard regression analysis. <h3>Results</h3> 3207 patients matched the inclusion criteria (age at inclusion 54.6±13.6 years, disease duration since the onset of first non-Raynaud's symptom: 8.1±7.7 years and from onset of Raynaud's phenomenon (RP) 12.3±11.2 years, male sex 13.2%, 33.4% diffuse subset, 96.4% presenting RP). At presentation, 1092 patients had a history of DUs (34.1%). DU history at baseline was the strongest predictor for the presence of active DUs at prospective visits, with a hazard ratio (HR, 95% confidence interval) of 2.55 (2.02-3.20), p&lt;0.001 when adjusting for age, gender and all parameters found significant in univariate analysis (elevated systolic pulmonary arterial pressure by ultrasound (sPAP-US), decreased carbon monoxyde lung diffusion (DLCO), anti-Scl70 antibodies). In univariate age-adjusted analysis, DUs were predictive of severe interstitial lung disease, defined as a forced vital capacity (FVC) of &lt;50% predicted: HR 1.75 (1.59-2.65), p&lt;0.01, and for severely decreased DLCO (&lt;40% predicted), HR 1.47(1.22-1.76), p&lt;0.001, but in multivariate analysis this association was not statistically significant anymore. There were 453 deaths recorded. The mean±SD time to death since RP onset was 17.3±11.3 years and since first non-Raynaud symptom 8.9±8.6 years. DUs were found to be predictive for death (HR 1.50,(1.15-1.96), p&lt;0.001) after adjusting for age, gender and all baseline parameters found to be significantly associated in the univariate analysis (disease subset, elevated sPAP-US, proteinuria, significant dyspnea, decreased FVC and DLCO, history of renal crisis and presence of anti-Scl70 antibodies). <h3>Conclusions</h3> A history of DUs at presentation is a predictor for the presence of DUs at follow-up and forecasts early mortality in patients with SSc. As such, the presence of DUs in a patient with SSc predicts a poor outcome. <b>Disclosure of Interest</b>: None Declared